Medicines Discovery Catapult ads

When drug discovery choices get complex, the right strategic guidance transforms uncertainty into traction. At Medicines Discovery Catapult, we de-risk R&D and accelerate your path forward. By grounding scientific strategy in patient and market reality, we turn complex choices into actionable, investable programmes. Make your next move count. Connect with our R&D Consultancy team today.

Drug discovery is high risk. When runway is short and funds are limited, fragmented data or missteps can stall your path to investors, partners, and regulators. Medicines Discovery Catapult applies deep scientific and translational expertise alongside patient and market insight to de-risk, accelerate, and define the fastest, safest route to success. Make your next move count. Speak with our R&D Consultancy experts today.

Great science needs a clear path to market. We apply deep scientific and translational expertise paired with critical patient and market insights to chart the safest and most efficient journey for your asset. Don't let incomplete strategy stall your progress to investors and regulators. Make your next move count with MDC R&D Consultancy.

Navigating the journey from concept to drug candidate requires clear answers at every milestone. Medicines Discovery Catapult provides the translational expertise and scientific clarity you need to make critical decisions swiftly. We help you define the fastest, safest, and most effective route to target success. Find clarity in your discovery journey.

When R&D choices get complex, the right strategic guidance turns uncertainty into clear momentum. Medicines Discovery Catapult de-risks early-stage drug discovery and accelerates your path forward. We combine scientific, translational, and market insights to turn complex choices into actionable, investable programmes. Make your next move count. Speak with our R&D Consultancy team today.

Internalisation and endosomal escape are two separate bottlenecks, and optimising for one does not guarantee the other. A formulation that drives high cellular uptake can still fail if only a fraction of its payload reaches the cytosol. At MDC, we have built an integrated evaluation platform that addresses both challenges across the preclinical pathway. From formulation selection to IND-enabling translational data, the platform is designed to build experimental confidence at every stage, aligned with the expectations of regulators and investors. If you are progressing an RNA therapeutic or LNP delivery programme, our team can help you identify the fastest route to the clinic. Speak to us.